Leukemia Research
Volume 27, Issue 9 , Pages 807-812 , September 2003

Loss of imprinting of IGF-II gene in children with acute lymphoblastic leukemia

  • Peter Vorwerk

      Affiliations

    • Department of Pediatric Oncology, Otto von Guericke University, Emanuel-Larisch-Weg 17-19, D-39112 Magdeburg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-391-6717223; fax: +49-391-67190562.
    • ,
  • Heike Wex

      Affiliations

    • Department of Pediatric Oncology, Otto von Guericke University, Emanuel-Larisch-Weg 17-19, D-39112 Magdeburg, Germany
    • ,
  • Cornelia Bessert

      Affiliations

    • Department of Pediatric Oncology, Otto von Guericke University, Emanuel-Larisch-Weg 17-19, D-39112 Magdeburg, Germany
    • ,
  • Bianka Hohmann

      Affiliations

    • Department of Pediatric Oncology, Otto von Guericke University, Emanuel-Larisch-Weg 17-19, D-39112 Magdeburg, Germany
    • ,
  • Uwe Schmidt

      Affiliations

    • Institute of Biometrics and Medical Informatics, Otto von Guericke University, Leipziger Straße 44, D-39112 Magdeburg, Germany
    • ,
  • Uwe Mittler

      Affiliations

    • Department of Pediatric Oncology, Otto von Guericke University, Emanuel-Larisch-Weg 17-19, D-39112 Magdeburg, Germany

Received 17 June 2002 ,Accepted 21 December 2002.

References 

  1. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, et al.  Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature. 1993;362(6422):749–751
  2. Feinberg AP. Genomic imprinting and gene activation in cancer. Nat. Genet. 1993;4(2):110–113
  3. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature. 1993;362(6422):747–749
  4. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, et al.  Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998;91(9):3144–3147
  5. Vorwerk P, Wex H, Hohmann B, Mohnike K, Schmidt U, Mittler U. Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia. Mol. Pathol. 2002;55(1):40–45
  6. Mohnike K, Kluba U, Mittler U, Aumann V, Vorwerk P, Blum W. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding protein-2 and -3 in children with acute lymphoblastic leukemia. Eur. J. Pediatr. 1996;155:81–86
  7. Wex H, Vorwerk P, Mohnike K, Bretschneider D, Kluba U, Aumann V, et al.  Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br. J. Cancer. 1998;78(4):515–520
  8. Mohnike K, Skjaerbeak C, Wex H, Vorwerk P, Kluba U, Bretschneider D et al. Low serum IGF in leukemia is due to sequestration. Horm Res 1998;50(S3):47 [abstract].
  9. Elmlinger MW, Bell M, Schuett BS, Langkamp M, Kutoh E, Ranke MB. Transactivation of the IGFBP-2 promoter in human tumor cell lines. Mol. Cell. Endocrinol. 2001;175(1–2):211–218
  10. Kiess W, Koepf G, Christiansen H, Blum WF. Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul. Pept. 1997;72(1):19–29
  11. Mohnike K, Kluba U, Aumann V, Wex H, Vorwerk P, Blum W et al. IGFBP-2 at diagnosis of lymphoid neoplasia predicts relapse risk. Growth Horm IGF Res 2000;10(4):A38 [abstract].
  12. Prosser J. Detecting single-base mutations. Trends Biotechnol. 1993;11(6):238–246
  13. Nishihara S, Hayashida T, Mitsuya K, Schulz TC, Ikeguchi M, Kaibara N, et al.  Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. Int. J. Oncol. 2000;17(2):317–322
  14. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J. Clin. Invest. 1994;94(1):445–448
  15. Ross JA, Schmidt PT, Perentesis JP, Davies SM. Genomic imprinting of H19 and insulin-like growth factor-2 in pediatric germ cell tumors. Cancer. 1999;85(6):1389–1394
  16. Zhan S, Shapiro DN, Helman LJ. Loss of imprinting of IGF2 in Ewing’s sarcoma. Oncogene. 1995;11(12):2503–2507
  17. Rainier S, Dobry CJ, Feinberg AP. Loss of imprinting in hepatoblastoma. Cancer Res. 1995;55(9):1836–1838
  18. Wada M, Seeger RC, Mizoguchi H, Koeffler HP. Maintenance of normal imprinting of H19 and IGF2 genes in neuroblastoma. Cancer Res. 1995;55(15):3386–3388
  19. Hattori H, Matsuzaki A, Suminoe A, Ihara K, Eguchi M, Tajiri T, et al.  Genomic imprinting of insulin-like growth factor-2 in infant leukemia and childhood neuroblastoma. Cancer. 2000;88(10):2372–2377
  20. Uyeno S, Aoki Y, Nata M, Sagisaka K, Kayama T, Yoshimoto T, et al.  IGF2 but not H19 shows loss of imprinting in human glioma. Cancer Res. 1996;56(23):5356–5359
  21. Muller S, Zirkel D, Westphal M, Zumkeller W. Genomic imprinting of IGF2 and H19 in human meningiomas. Eur. J. Cancer. 2000;36(5):651–655
  22. Nonomura N, Nishimura K, Miki T, Kanno N, Kojima Y, Yokoyama M, et al.  Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma. Cancer Res. 1997;57(13):2575–2577
  23. Oda H, Kume H, Shimizu Y, Inoue T, Ishikawa T. Loss of imprinting of igf2 in renal-cell carcinomas. Int. J. Cancer. 1998;75(3):343–346
  24. Kim HT, Choi BH, Niikawa N, Lee TS, Chang SI. Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. Am. J. Med. Genet. 1998;80(4):391–395
  25. Chen CL, Ip SM, Cheng D, Wong LC, Ngan HY. Loss of imprinting of the IGF-II and H19 genes in epithelial ovarian cancer. Clin. Cancer Res. 2000;6(2):474–479
  26. Nonomura N, Miki T, Nishimura K, Kanno N, Kojima Y, Okuyama A. Altered imprinting of the H19 and insulin-like growth factor II genes in testicular tumors. J. Urol. 1997;157(5):1977–1979
  27. Yballe CM, Vu TH, Hoffman AR. Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor. J. Clin. Endocrinol. Metab. 1996;81(4):1607–1612
  28. Yun K, Soejima H, Merrie AE, McCall JL, Reeve AE. Analysis of IGF2 gene imprinting in breast and colorectal cancer by allele specific-PCR. J. Pathol. 1999;187(5):518–522
  29. Takano Y, Shiota G, Kawasaki H. Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer. Oncology. 2000;59(3):210–216
  30. Mori M, Inoue H, Shiraishi T, Mimori K, Shibuta K, Nakashima H, et al.  Relaxation of insulin-like growth factor 2 gene imprinting in esophageal cancer. Int. J. Cancer. 1996;68(4):441–446
  31. Roy RN, Gerulath AH, Cecutti A, Bhavnani BR. Loss of IGF-II imprinting in endometrial tumors: overexpression in carcinosarcoma. Cancer Lett. 2000;153(1–2):67–73
  32. Kohda M, Hoshiya H, Katoh M, Tanaka I, Masuda R, Takemura T, et al.  Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol. Carcinog. 2001;31(4):184–191
  33. Rainho CA, Kowalski LP, Rogatto SR. Loss of imprinting and loss of heterozygosity on 11p15.5 in head and neck squamous cell carcinomas. Head Neck. 2001;23(10):851–859
  34. Hodzic D, Delacroix L, Willemsen P, Bensbaho K, Collette J, Broux R, et al.  Characterization of the IGF system and analysis of the possible molecular mechanisms leading to IGF-II overexpression in a mesothelioma. Horm. Metab. Res. 1997;29(11):549–555
  35. Wu HK, Weksberg R, Minden MD, Squire JA. Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia. Biochem. Biophys. Res. Commun. 1997;231(2):466–472
  36. Liu Y, Yang B, Zhu H, Wang J. Loss of imprinting of insulin-like growth factor II gene in acute myeloid leukemia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2000;17(1):39–41.
  37. Burns JL, Jackson DA, Hassan AB. A view through the clouds of imprinting. FASEB J. 2001;15(10):1694–1703
  38. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, et al.  Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms’ tumor. J. Natl. Cancer Inst. 2001;93(22):1698–1703
  39. Sakatani T, Wei M, Katoh M, Okita C, Wada D, Mitsuya K, et al.  Epigenetic heterogeneity at imprinted loci in normal populations. Biochem. Biophys. Res. Commun. 2001;283(5):1124–1130
  40. Kinouchi Y, Hiwatashi N, Higashioka S, Nagashima F, Chida M, Toyota T. Relaxation of imprinting of the insulin-like growth factor II gene in colorectal cancer. Cancer Lett. 1996;107(1):105–108
  41. Tadokoro K, Fujii H, Inoue T, Yamada M. Polymerase chain reaction (PCR) for detection of ApaI polymorphism at the insulin like growth factor II gene (IGF2). Nucleic Acids Res. 1991;19(24):6967
  42. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La CA. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 2001;98(2):591–596
  43. Winkler R, Delacroix L, Bensbaho K, Lambert S, Collette J, Hodzic D. IGF-II in primary human colorectal tumors: peptide level, activated promoters, parental imprinting and gene rearrangement. Horm. Metab. Res. 1999;31(2–3):148–154
  44. Micha AE, Hahnel S, Friess H, Buchler MW, Adler G, Gress TM. Genomic imprinting of IGF-II and H19 in adult human pancreatic tissues. Digestion. 1999;60(5):477–483
  45. Elmlinger MW, Sanatani MS, Bell M, Dannecker GE, Ranke MB. Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. Eur. J. Endocrinol. 1998;138(3):337–343
  46. Muller HL, Oh Y, Gargosky SE, Wilson KF, Lehrnbecher T, Rosenfeld RG. Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia. Pediatr. Res. 1994;35(6):720–724
  47. Vetter U, Schlickenrieder JH, Zapf J, Hartmann W, Heit W, Hitzler H, et al.  Human leukemic cells: receptor binding and biological effects of insulin and insulin-like growth factors. Leuk. Res. 1986;10(10):1201–1207
  48. Zumkeller W, Burdach S. The insulin-like growth factor system in normal and malignant hematopoietic cells. Blood. 1999;94(11):3653–3657

PII: S0145-2126(03)00014-6

doi: 10.1016/S0145-2126(03)00014-6

Leukemia Research
Volume 27, Issue 9 , Pages 807-812 , September 2003

Article Tools

* Image Usage & Resolution